Iteos Home

Historical Price Lookup

Home / Investors / Historical Price Lookup

Historical Price Lookup

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer.

Our innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1.

iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

For investors

Discover more about iTeos Therapeutics, our science, and our high potential for investment.

Historical Price Lookup

Week of November 18, 2024

Date Requested November 18, 2024
Open Price
$8.29
Closing Price
$7.88
Day's High
$8.29
Day's Low
$7.82
Volume
501,512
Split Adjustment Factor
1:1
Date Requested November 19, 2024
Open Price
$7.74
Closing Price
$7.90
Day's High
$7.91
Day's Low
$7.66
Volume
455,836
Split Adjustment Factor
1:1
Date Requested November 20, 2024
Open Price
$8.01
Closing Price
$7.85
Day's High
$8.38
Day's Low
$7.82
Volume
502,265
Split Adjustment Factor
1:1

NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. The closing price is not necessarily indicative of future price performance.

Minimum 15 minutes delayed. Source:

Child kissing a woman

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.